In conclusion, our study provides evidence that co-expression of CXCR2 in CAR-T cells can enhance antitumor effects, increase T-cell recruitment and proliferation at PDAC tumor sites, and does not produce cellular toxicity. This evidence concerns the gene CXCR2 and neoplasm.